Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK’s Malaria Drug Tafenoquine Heads To US FDA Panel Review With Agency Backing

Executive Summary

Approval could bring GlaxoSmithKline a tropical disease priority review voucher.


Related Content

Tafenoquine Redux: 60 Degrees Pharma’s Malaria Drug Gets Its Turn At US FDA Panel
GSK's Tafenoquine Faces Questions Over Review Pathways At US FDA Panel
GSK Moves Closer To Priority Review Voucher As US Panel Backs Malaria Drug Tafenoquine
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts